P226 Disability in Crohn’s Disease Patients at diagnosis: Findings from the CROCO (Crohn´s Disease Cohort) study

Background Crohn’s disease (CD) can lead to progressive bowel damage and disability. Disability has been proposed by the SPIRIT-IOIBD consensus as an endpoint in disease-modification trials. Despite this, there is scarce data on disability at CD diagnosis. Methods The Crohn´s Disease Cohort (CROCO)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Crohn's and colitis 2024-01, Vol.18 (Supplement_1), p.i563-i564
Hauptverfasser: Revés, J, Roager Madsen, G, Burisch, J, Wong, C, Arebi, N, Bonnet-Dodel, M, Buisson, A, Gatt, K, Ellul, P, Vieujean, S, Ordas, I, Duricova, D, Rodríguez-Lago, I, Sebastian, S, Mocanu, I, Kaimakliotis, I, Goldis, A, Hernandez, V, Nachury, M, Fumery, M, Alloca, M, Pedersen, N, Barberio, B, Guedes, A, Ribeiro, R, Ungaro, R, Mary, J Y, Bigot, N, Lambert, J, Colombel, J F, Torres, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Crohn’s disease (CD) can lead to progressive bowel damage and disability. Disability has been proposed by the SPIRIT-IOIBD consensus as an endpoint in disease-modification trials. Despite this, there is scarce data on disability at CD diagnosis. Methods The Crohn´s Disease Cohort (CROCO) is an ongoing prospective cohort study with newly diagnosed CD patients (within 12 months of diagnosis) aiming to assess the evolution of bowel damage and disability over time. Disability evaluation was conducted via the validated IBD-Disability Index (IBD-DI), which encompasses 14 questions ranging from 0-100 intended to measure overall health, sleep and energy, affect, body image, pain, defecation, interpersonal activities, and work and education.1 This study explored disability scores (DS) and their association with disease features and activity at diagnosis in patients with newly diagnosed CD. The IBD-DI was categorized as previously reported in no disability (scores 0-20), mild disability (scores 21-35), and moderate-severe disability (scores 36-100).2 Results From a cohort of 261 patients [58% male, median age at diagnosis of 35yo (IQR 25-49)], 224 completed the IBD-DI at inclusion. Median time from inclusion to baseline visit was 4 months (IQR 1.7-7.8). Most patients presented with ileal or ileocolonic disease location (87%) and an inflammatory phenotype (69%); 16% had perianal disease and 27% had extraintestinal manifestations. At inclusion, 21% had been hospitalised, and 10% had a CD-related surgery. Treatments included steroids (56%), immunosuppressants (34%), and anti-TNF therapy (40%). The median DS at inclusion was 22.2 (IQR 10.4-37.9), with 48% exhibiting no disability and 30% displaying moderate-severe disability (Figure 1). Moderate-severe disability at baseline visit was associated with female gender (OR 3.65, 95%CI 2.01-6.62, p
ISSN:1873-9946
1876-4479
DOI:10.1093/ecco-jcc/jjad212.0356